Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
NCT07730125
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
67
Enrollment
INDUSTRY
Sponsor class
Conditions
HR-positive, HER2-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer
Prostate Cancer
Interventions
DRUG:
CRG-150
Sponsor
CoRegen, Inc.
Collaborators
[object Object]